Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Breast Neoplasms 9Head and Neck Neoplasms 6Squamous Cell Carcinoma of Head and Neck 4Neoplasms 4Neoplasm Metastasis 4Lung Neoplasms 4Ovarian Neoplasms 3Nasopharyngeal Carcinoma 3Esophageal Squamous Cell Carcinoma 3Colorectal Neoplasms 3Anus Neoplasms 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Rectal Neoplasms 2Pancreatic Neoplasms 2Oropharyngeal Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Small Cell Lung Carcinoma 1Skin Neoplasms 1Select Advanced Solid Tumors 1SCLC, Extensive Stage 1SCLC 1Retinoblastoma 1Retinal Neoplasms 1Recurrence 1Radiation Therapy 1Prostatic Neoplasms 1

Interventions

trastuzumab deruxtecan 1sintilimab 1pembrolizumab 1durvalumab 1cabozantinib 1Drug Therapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Gastric Adenocarcinoma × Drug Therapy × Clear all
NCT06667050 2024-10-31

CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer

West China Hospital

Phase 2 Active not recruiting
58 enrolled
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡